1. Pink Sheet
  2. >>Regions
  3. >>Europe

Fresh EU-Wide Challenge To Sovaldi Patent Puts The Spotlight On Drug Pricing Again

 
• By Vibha Sharma
  
Generate a summary of this article
Listen to this article
Beta

Access to affordable medicines has become a global challenge. A new chapter has been added to the struggle as several EU-based civil society groups join hands to challenge Gillead’s sofosbuvir patent in a bid to increase access to affordable hepatitis C treatment.

Medical pills and euros
Drug Pricing In Focus Again With Fresh EU-Wide Challenge To Sovaldi Patent • Source: Shutterstock

The ongoing debate around the increasing prices of new medicines received fresh impetus after 30-odd civil society organizations filed another EU-wide patent challenge against Gilead’s hepatitis C drug Sovaldi (sofosbuvir) claiming that the “science behind sofosbuvir isn’t new”. The organizations added that the drug is too costly and cannot be afforded by “millions of people who need it”.

It could be 18 months before the case comes up for hearing at the European Patent Office, Médecins Sans Frontières...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By Saba Afreen

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     
    • By Anabel Costa-Ferreira and Ian Schofield

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography